{"id":7326,"date":"2014-10-30T18:17:48","date_gmt":"2014-10-30T18:17:48","guid":{"rendered":"https:\/\/www.nicox.com\/information-financiere-du-troisieme-trimestre-2014\/"},"modified":"2014-10-30T18:17:48","modified_gmt":"2014-10-30T18:17:48","slug":"information-financiere-du-troisieme-trimestre-2014","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/","title":{"rendered":"Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014"},"content":{"rendered":"<ul>\n<li>\n  <strong>Le chiffre d&rsquo;affaires totalise \u20ac4,5 millions pour la p\u00e9riode de neuf mois se terminant le 30 septembre 2014, contre \u20ac0,3 million pour la m\u00eame p\u00e9riode en 2013&nbsp;<\/strong><\/li>\n<li>\n  <strong>L&rsquo;acquisition d\u00e9finitive d&rsquo;Aciex Therapeutics, Inc. renforce significativement le portefeuille de m\u00e9dicaments en d\u00e9veloppement de Nicox&nbsp;<\/strong><\/li>\n<li>\n  <strong>Les r\u00e9sultats positifs de phase 3 pour VESNEO (latanoprost\u00e8ne bunod) confortent son fort potentiel commercial<\/strong><\/li>\n<li>\n  <strong>L&rsquo;acquisition du fran\u00e7ais Doliage consolide les sources de revenus et l\u2019infrastructure commerciale europ\u00e9enne&nbsp;<\/strong><\/li>\n<\/ul>\n<div>\n Sophia Antipolis, France.<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n <strong>Nicox S.A. <\/strong>(NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, publie aujourd\u2019hui son chiffre d\u2019affaires et sa tr\u00e9sorerie pour les neuf premiers mois de l\u2019ann\u00e9e 2014.<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n <strong>Michele Garufi, Pr\u00e9sident Directeur G\u00e9n\u00e9ral de Nicox,<\/strong> a d\u00e9clar\u00e9 : <em>\u00ab Au cours du troisi\u00e8me trimestre 2014, nous avons r\u00e9alis\u00e9 d\u2019importants progr\u00e8s dans la constitution de notre portefeuille de m\u00e9dicaments ophtalmiques en d\u00e9veloppement, notamment gr\u00e2ce aux r\u00e9sultats positifs de phase 3 obtenus avec VESNEO et \u00e0 l&rsquo;acquisition r\u00e9cente d&rsquo;Aciex Therapeutics, Inc. Nicox a maintenant deux m\u00e9dicaments en d\u00e9veloppement ayant termin\u00e9 les essais cliniques de phase 3, ce qui renforce nos perspectives en tant que Groupe international comp\u00e9titif sur les march\u00e9s de l&rsquo;ophtalmologie. \u00bb<\/em><\/div>\n<div>\n &nbsp;<\/div>\n<div>\n <b>Pour lire le communiqu\u00e9 de presse merci de t\u00e9l\u00e9charger le PDF&nbsp;<\/b><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le chiffre d&rsquo;affaires totalise \u20ac4,5 millions pour la p\u00e9riode de neuf mois se terminant le 30 septembre 2014, contre \u20ac0,3 million pour la m\u00eame p\u00e9riode en 2013&nbsp; L&rsquo;acquisition d\u00e9finitive d&rsquo;Aciex Therapeutics, Inc. renforce significativement le portefeuille de m\u00e9dicaments en d\u00e9veloppement de Nicox&nbsp; Les r\u00e9sultats positifs de phase 3 pour VESNEO (latanoprost\u00e8ne bunod) confortent son fort [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7326","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Le chiffre d&rsquo;affaires totalise \u20ac4,5 millions pour la p\u00e9riode de neuf mois se terminant le 30 septembre 2014, contre \u20ac0,3 million pour la m\u00eame p\u00e9riode en 2013&nbsp; L&rsquo;acquisition d\u00e9finitive d&rsquo;Aciex Therapeutics, Inc. renforce significativement le portefeuille de m\u00e9dicaments en d\u00e9veloppement de Nicox&nbsp; Les r\u00e9sultats positifs de phase 3 pour VESNEO (latanoprost\u00e8ne bunod) confortent son fort [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-30T18:17:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/information-financiere-du-troisieme-trimestre-2014\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/information-financiere-du-troisieme-trimestre-2014\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014\",\"datePublished\":\"2014-10-30T18:17:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/information-financiere-du-troisieme-trimestre-2014\\\/\"},\"wordCount\":241,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/information-financiere-du-troisieme-trimestre-2014\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/information-financiere-du-troisieme-trimestre-2014\\\/\",\"name\":\"Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2014-10-30T18:17:48+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/information-financiere-du-troisieme-trimestre-2014\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014 - Nicox","og_description":"Le chiffre d&rsquo;affaires totalise \u20ac4,5 millions pour la p\u00e9riode de neuf mois se terminant le 30 septembre 2014, contre \u20ac0,3 million pour la m\u00eame p\u00e9riode en 2013&nbsp; L&rsquo;acquisition d\u00e9finitive d&rsquo;Aciex Therapeutics, Inc. renforce significativement le portefeuille de m\u00e9dicaments en d\u00e9veloppement de Nicox&nbsp; Les r\u00e9sultats positifs de phase 3 pour VESNEO (latanoprost\u00e8ne bunod) confortent son fort [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/","og_site_name":"Nicox","article_published_time":"2014-10-30T18:17:48+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/"},"author":{"name":"","@id":""},"headline":"Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014","datePublished":"2014-10-30T18:17:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/"},"wordCount":241,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/","url":"https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/","name":"Nicox : information financi\u00e8re du troisi\u00e8me trimestre 2014 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2014-10-30T18:17:48+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/information-financiere-du-troisieme-trimestre-2014\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7326"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7326\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}